GITNUXREPORT 2026

Cholesterol Statistics

High cholesterol is a widespread global health risk, contributing to millions of preventable deaths annually.

Min-ji Park

Research Analyst focused on sustainability and consumer trends.

First published: Feb 13, 2026

Our Commitment to Accuracy

Rigorous fact-checking · Reputable sources · Regular updatesLearn more

Statistic 1

LDL cholesterol is 70-80% carried by low-density lipoprotein particles in human plasma

Statistic 2

HDL cholesterol constitutes about 20-30% of total circulating cholesterol

Statistic 3

Cholesterol synthesis in the liver accounts for 70-80% of total body cholesterol production daily

Statistic 4

HMG-CoA reductase enzyme regulates 90% of hepatic cholesterol biosynthesis rate

Statistic 5

LDL particles have a density of 1.019-1.063 g/mL and diameter 18-25 nm

Statistic 6

Cholesterol efflux capacity of HDL is mediated by ABCA1 transporter, removing 4-5% of cellular cholesterol per cycle

Statistic 7

PCSK9 protein degrades 50-70% of LDL receptors daily in hepatocytes

Statistic 8

SREBP-2 transcription factor induces 30 genes involved in cholesterol homeostasis

Statistic 9

Cholesterol absorption in intestine is 40-60% efficient via NPC1L1 transporter

Statistic 10

VLDL particles secrete 2-3 mg cholesterol per hour into plasma from liver

Statistic 11

ApoB-100 protein is present on 90% of plasma lipoproteins containing cholesterol

Statistic 12

Reverse cholesterol transport removes 5-10 grams of cholesterol daily via HDL

Statistic 13

Cholesterol crystal formation in plaques involves 20-30% volume in advanced atherosclerosis

Statistic 14

LCAT enzyme esterifies 70% of plasma cholesterol on HDL particles

Statistic 15

Niemann-Pick C1 protein regulates 50% of lysosomal cholesterol export

Statistic 16

CETP transfers 80% of cholesteryl esters from HDL to VLDL/LDL

Statistic 17

Mevalonate pathway produces 1 gram of cholesterol per day in adults

Statistic 18

OxLDL induces foam cell formation via CD36 receptor in 60% of macrophages

Statistic 19

SR-B1 mediates selective uptake of 20-50% HDL cholesteryl esters in liver

Statistic 20

ACAT2 esterifies 90% of cholesterol in enterocytes for chylomicron assembly

Statistic 21

LXR agonists upregulate ABCA1 by 10-fold increasing efflux

Statistic 22

Cholesterol 7-alpha-hydroxylase (CYP7A1) initiates 50% of bile acid synthesis

Statistic 23

ApoE polymorphism affects 20-30% variation in LDL levels

Statistic 24

Sphingomyelinase activates 40% of LDL aggregation in plaques

Statistic 25

Farnesyl pyrophosphate intermediates inhibit LDL receptor by 70%

Statistic 26

HDL maturation involves PLTP transferring 60% phospholipids

Statistic 27

Familial hypercholesterolemia FH heterozygotes have 2-3 fold elevated LDL

Statistic 28

NPC2 protein transfers cholesterol at rate of 1000 molecules/second

Statistic 29

Oxidized phospholipids on LDL activate TLR4 in 50% of endothelial cells

Statistic 30

ABCG5/G8 transporters limit intestinal absorption to 50% maximum

Statistic 31

Desirable LDL <100 mg/dL per AHA guidelines for low risk

Statistic 32

Target LDL <70 mg/dL for very high CVD risk patients

Statistic 33

HDL <40 mg/dL men or <50 mg/dL women considered low risk factor

Statistic 34

Non-HDL goal <130 mg/dL for moderate risk per NCEP ATP III

Statistic 35

Fasting lipid panel recommended every 4-6 years starting age 20

Statistic 36

Total cholesterol 200-239 mg/dL borderline high

Statistic 37

LDL 160-189 mg/dL high, warrants lifestyle intervention

Statistic 38

Triglycerides <150 mg/dL normal, >500 mg/dL very high per AHA

Statistic 39

Cascade screening for FH targets 1st degree relatives 80% yield

Statistic 40

Apolipoprotein B target <90 mg/dL for high risk

Statistic 41

Lp(a) >50 mg/dL considered risk enhancer per 2018 AHA

Statistic 42

Risk assessment using PCE calculator 10-year ASCVD risk threshold 7.5%

Statistic 43

Children of FH parents screened age 0-10, LDL >190 mg/dL diagnostic

Statistic 44

Statin intensity high if LDL drop ≥50%, moderate 30-50%

Statistic 45

ACC/AHA recommends lipid panel every 5 years age 40-75

Statistic 46

ESC guideline LDL <55 mg/dL very high risk post-ACS

Statistic 47

Optimal triglycerides <100 mg/dL for insulin resistance prevention

Statistic 48

Direct LDL measurement preferred if triglycerides >400 mg/dL

Statistic 49

HDL ≥60 mg/dL protective against CVD per NCEP

Statistic 50

Universal screening lipids age 9-11 and 17-21 per AAP

Statistic 51

Risk enhancers include high LDL-P >1000 nmol/L

Statistic 52

Target apoB <80 mg/dL very high risk ESC 2019

Statistic 53

Nonfasting lipids acceptable for initial screening per EAS

Statistic 54

LDL ≥190 mg/dL in adults <40 initiates high intensity statin

Statistic 55

According to the CDC, approximately 93 million U.S. adults aged 20 and older have elevated total cholesterol levels above 200 mg/dL

Statistic 56

The World Health Organization reports that high cholesterol contributes to 2.6 million deaths annually worldwide, representing 4.4% of all global deaths

Statistic 57

In Europe, the European Heart Network states that 54% of adults have total cholesterol levels above the recommended 5 mmol/L threshold

Statistic 58

A NHANES survey from 2017-2018 found that 38.7% of U.S. adults had high LDL cholesterol (≥130 mg/dL)

Statistic 59

Globally, 39% of adults aged 18+ had high cholesterol in 2018 per WHO STEPS survey data

Statistic 60

In India, the ICMR-INDIAB study reported a prevalence of hypercholesterolemia at 13.9% in urban populations

Statistic 61

Australian Bureau of Statistics data shows 32% of adults had high total cholesterol (>5.5 mmol/L) in 2011-12

Statistic 62

In the UK, 59% of adults have cholesterol levels above 5 mmol/L according to BHF

Statistic 63

Framingham Heart Study offspring cohort indicated 45% prevalence of high cholesterol in middle-aged adults

Statistic 64

In China, the China Health and Nutrition Survey found 32.1% hypercholesterolemia prevalence in 2009

Statistic 65

Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) reported 31.1% high LDL-C prevalence

Statistic 66

In South Africa, 52.6% of adults had total cholesterol >5 mmol/L per WHO STEPS 2016

Statistic 67

Japanese National Health and Nutrition Survey 2019 showed 27.4% dyslipidemia prevalence

Statistic 68

In Mexico, ENSANUT 2018 found 47.5% high cholesterol in adults

Statistic 69

Canadian Heart Health Surveys reported 42% prevalence of high cholesterol in 1986-1992

Statistic 70

In Germany, DEGS1 survey 2008-2011 indicated 30.8% high total cholesterol

Statistic 71

Italian Osservatorio Epidemiologico Cardiovascolare reported 38% hypercholesterolemia in adults

Statistic 72

In Russia, 56.9% of adults had high cholesterol per 2013 survey

Statistic 73

Swedish National Public Health Survey 2018 showed 25% high cholesterol prevalence

Statistic 74

In the Netherlands, 60% of adults over 30 have elevated cholesterol per RIVM

Statistic 75

New Zealand Health Survey 2017/18 found 32% high total cholesterol

Statistic 76

In Turkey, TEKHARF study 2017 reported 46.2% hypercholesterolemia

Statistic 77

Saudi Heart Association data indicates 41% prevalence in adults

Statistic 78

In Egypt, 44.4% of adults have high cholesterol per NCD survey

Statistic 79

Korean National Health Insurance data 2015 showed 19.6% severe hypercholesterolemia

Statistic 80

In Iran, 40.2% prevalence from cross-sectional studies meta-analysis

Statistic 81

Polish NATPOL 2011 study found 52% high cholesterol in adults

Statistic 82

In Argentina, 34.4% hypercholesterolemia per 2018 survey

Statistic 83

Norwegian HUNT3 study reported 45% elevated cholesterol

Statistic 84

In Spain, ESCARVAL study 2008-2010 showed 39% high LDL-C

Statistic 85

High cholesterol increases CVD risk by 2.5-fold per 1 mmol/L LDL rise

Statistic 86

Each 38.7 mg/dL LDL reduction lowers major vascular events by 22%

Statistic 87

Low HDL (<40 mg/dL men) triples coronary heart disease risk

Statistic 88

High cholesterol causes 4 million premature deaths yearly globally

Statistic 89

Familial hypercholesterolemia untreated leads to 50% MI risk by age 50

Statistic 90

Statin therapy reduces stroke risk by 21% per 1 mmol/L LDL drop

Statistic 91

Non-HDL cholesterol >3.37 mmol/L doubles CVD mortality

Statistic 92

Cholesterol embolization syndrome occurs in 1.4% post-angioplasty

Statistic 93

High LDL accelerates aortic stenosis progression by 2-fold

Statistic 94

Hypercholesterolemia increases PAD risk by 2.2-fold

Statistic 95

In women, high cholesterol raises CVD death risk 4.5-fold post-menopause

Statistic 96

Lp(a) >50 mg/dL elevates MI risk 2-3 fold

Statistic 97

Cholesterol gallstones comprise 80% of gallstones in Western populations

Statistic 98

High triglycerides (>5 mmol/L) increase pancreatitis risk 10-fold

Statistic 99

Dyslipidemia contributes to 30% of ischemic strokes

Statistic 100

In FH homozygotes, CVD events occur by age 20 in 75%

Statistic 101

Remnant cholesterol >1 mmol/L raises CVD risk 40% per unit

Statistic 102

High cholesterol links to 20% higher dementia risk

Statistic 103

LDL >160 mg/dL triples carotid plaque progression

Statistic 104

Statins reduce all-cause mortality by 14% in high cholesterol patients

Statistic 105

High on-treatment LDL >70 mg/dL has 2-fold recurrent event risk

Statistic 106

Cholesterol burden predicts 25% AFib risk increase

Statistic 107

Xanthomas occur in 75% of FH heterozygotes untreated

Statistic 108

Hypercholesterolemia worsens HF prognosis by 30%

Statistic 109

LDL particle number >1300 nmol/L doubles CVD risk vs concentration

Statistic 110

High cholesterol in youth predicts adult CVD 5-fold

Statistic 111

Optimal total cholesterol <150 mg/dL reduces mortality 50%

Statistic 112

HDL dysfunction increases MI risk 3-fold despite high levels

Statistic 113

Daily cholesterol intake averages 300-500 mg in Western diets

Statistic 114

Obesity increases LDL cholesterol by 10-15% per 10 kg weight gain

Statistic 115

Smoking raises LDL by 5-10% and lowers HDL by 10%

Statistic 116

Type 2 diabetes elevates triglycerides and lowers HDL by 20-30%

Statistic 117

Sedentary lifestyle correlates with 12% higher total cholesterol

Statistic 118

Family history doubles risk of hypercholesterolemia

Statistic 119

Postmenopausal women see 10-15% LDL rise due to estrogen decline

Statistic 120

Trans fat intake raises LDL by 0.03 mmol/L per gram daily

Statistic 121

Hypertension coexists with high cholesterol in 40% of cases

Statistic 122

Age over 45 in men or 55 in women increases cholesterol risk by 2-fold

Statistic 123

South Asian ethnicity has 20% higher dyslipidemia prevalence

Statistic 124

Alcohol excess lowers HDL but raises triglycerides by 20%

Statistic 125

Hypothyroidism elevates LDL by 30% via reduced clearance

Statistic 126

Chronic kidney disease doubles hypercholesterolemia odds

Statistic 127

Saturated fat >10% calories raises LDL by 10%

Statistic 128

PCOS increases dyslipidemia risk by 70%

Statistic 129

HIV infection on ART raises cholesterol by 10-20%

Statistic 130

Stress hormones increase LDL by 10% acutely

Statistic 131

Low fiber diet correlates with 15% higher cholesterol absorption

Statistic 132

Metabolic syndrome present in 50% of high cholesterol patients

Statistic 133

African American men have 10% lower average HDL than whites

Statistic 134

Sleep apnea raises cholesterol by 10-15%

Statistic 135

Corticosteroid use elevates cholesterol 20-30%

Statistic 136

High glycemic index diets increase triglycerides 20%

Statistic 137

Rheumatoid arthritis patients have 10% higher LDL

Statistic 138

Beta-blockers raise triglycerides by 20-50%

Statistic 139

Pregnancy increases total cholesterol by 25-50% in third trimester

Statistic 140

Psoriasis doubles dyslipidemia risk

Statistic 141

Shift work disrupts lipids with 8% higher cholesterol

Statistic 142

High fructose intake raises LDL 10%

Statistic 143

Nephrotic syndrome elevates cholesterol 3-5 fold

Statistic 144

Statins reduce LDL by 20-60% dose-dependently

Statistic 145

Ezetimibe adds 15-25% LDL reduction to statin

Statistic 146

PCSK9 inhibitors lower LDL 50-70% in FH patients

Statistic 147

Bempedoic acid reduces LDL 18% monotherapy

Statistic 148

Plant sterols 2g/day lower LDL 10%

Statistic 149

Niacin raises HDL 15-35% but no CVD benefit

Statistic 150

Fibrates reduce triglycerides 20-50%

Statistic 151

Aerobic exercise 150 min/week lowers LDL 5-10%

Statistic 152

Mediterranean diet reduces LDL 10-15%

Statistic 153

Soluble fiber 5-10g/day lowers LDL 5%

Statistic 154

Weight loss 5-10% reduces total cholesterol 10%

Statistic 155

Omega-3 4g/day lowers triglycerides 30%

Statistic 156

Lomitapide in FH homozygotes reduces LDL 40-50%

Statistic 157

Mipomersen ASO lowers LDL 40% in FH

Statistic 158

Inclisiran siRNA reduces LDL 52% at 17 months

Statistic 159

Portfolio diet lowers LDL 30% comparable to lovastatin

Statistic 160

Rosuvastatin 20mg reduces LDL 55%

Statistic 161

Lifestyle intervention alone lowers cholesterol 10-20% in mild cases

Statistic 162

Bile acid sequestrants lower LDL 15-30%

Statistic 163

Smoking cessation increases HDL 10% within 1 year

Statistic 164

Soy protein 25g/day lowers LDL 3-5%

Statistic 165

Nuts 1oz/day reduce LDL 5%

Statistic 166

Green tea catechins lower LDL 5-10 mg/dL

Statistic 167

Resistant starch intake reduces cholesterol absorption 10%

Statistic 168

Probiotics lower LDL 5-10% in meta-analysis

Statistic 169

Garlic supplements reduce total cholesterol 10-15 mg/dL short-term

Statistic 170

Evolocumab reduces CVD events 20%

Statistic 171

Alirocumab lowers LDL 62% max

Statistic 172

Intensive statin doubles plaque regression vs moderate

1/172

Sources

Trusted by 500+ publications

+497

While shockingly high cholesterol levels silently afflict tens of millions globally, this crucial number in your blood test reveals far more than you might think.

Key Takeaways

According to the CDC, approximately 93 million U.S. adults aged 20 and older have elevated total cholesterol levels above 200 mg/dL
The World Health Organization reports that high cholesterol contributes to 2.6 million deaths annually worldwide, representing 4.4% of all global deaths
In Europe, the European Heart Network states that 54% of adults have total cholesterol levels above the recommended 5 mmol/L threshold
LDL cholesterol is 70-80% carried by low-density lipoprotein particles in human plasma
HDL cholesterol constitutes about 20-30% of total circulating cholesterol
Cholesterol synthesis in the liver accounts for 70-80% of total body cholesterol production daily
Daily cholesterol intake averages 300-500 mg in Western diets
Obesity increases LDL cholesterol by 10-15% per 10 kg weight gain
Smoking raises LDL by 5-10% and lowers HDL by 10%
High cholesterol increases CVD risk by 2.5-fold per 1 mmol/L LDL rise
Each 38.7 mg/dL LDL reduction lowers major vascular events by 22%
Low HDL (<40 mg/dL men) triples coronary heart disease risk
Desirable LDL <100 mg/dL per AHA guidelines for low risk
Target LDL <70 mg/dL for very high CVD risk patients
HDL <40 mg/dL men or <50 mg/dL women considered low risk factor

High cholesterol is a widespread global health risk, contributing to millions of preventable deaths annually.

Biological Mechanisms

LDL cholesterol is 70-80% carried by low-density lipoprotein particles in human plasma
HDL cholesterol constitutes about 20-30% of total circulating cholesterol
Cholesterol synthesis in the liver accounts for 70-80% of total body cholesterol production daily
HMG-CoA reductase enzyme regulates 90% of hepatic cholesterol biosynthesis rate
LDL particles have a density of 1.019-1.063 g/mL and diameter 18-25 nm
Cholesterol efflux capacity of HDL is mediated by ABCA1 transporter, removing 4-5% of cellular cholesterol per cycle
PCSK9 protein degrades 50-70% of LDL receptors daily in hepatocytes
SREBP-2 transcription factor induces 30 genes involved in cholesterol homeostasis
Cholesterol absorption in intestine is 40-60% efficient via NPC1L1 transporter
VLDL particles secrete 2-3 mg cholesterol per hour into plasma from liver
ApoB-100 protein is present on 90% of plasma lipoproteins containing cholesterol
Reverse cholesterol transport removes 5-10 grams of cholesterol daily via HDL
Cholesterol crystal formation in plaques involves 20-30% volume in advanced atherosclerosis
LCAT enzyme esterifies 70% of plasma cholesterol on HDL particles
Niemann-Pick C1 protein regulates 50% of lysosomal cholesterol export
CETP transfers 80% of cholesteryl esters from HDL to VLDL/LDL
Mevalonate pathway produces 1 gram of cholesterol per day in adults
OxLDL induces foam cell formation via CD36 receptor in 60% of macrophages
SR-B1 mediates selective uptake of 20-50% HDL cholesteryl esters in liver
ACAT2 esterifies 90% of cholesterol in enterocytes for chylomicron assembly
LXR agonists upregulate ABCA1 by 10-fold increasing efflux
Cholesterol 7-alpha-hydroxylase (CYP7A1) initiates 50% of bile acid synthesis
ApoE polymorphism affects 20-30% variation in LDL levels
Sphingomyelinase activates 40% of LDL aggregation in plaques
Farnesyl pyrophosphate intermediates inhibit LDL receptor by 70%
HDL maturation involves PLTP transferring 60% phospholipids
Familial hypercholesterolemia FH heterozygotes have 2-3 fold elevated LDL
NPC2 protein transfers cholesterol at rate of 1000 molecules/second
Oxidized phospholipids on LDL activate TLR4 in 50% of endothelial cells
ABCG5/G8 transporters limit intestinal absorption to 50% maximum

Biological Mechanisms Interpretation

Human biology runs on a finely-tuned assembly line where the liver works overtime to make most of our cholesterol, bad LDL particles deliver it to trouble spots, and good HDL particles work an arduous reverse shift to haul only a fraction back, all while a constant molecular tug-of-war—involving fragile receptors, vigilant transporters, and rival enzymes—struggles to keep this essential but treacherous lipid from crystallizing into the plaques that threaten the whole operation.

Clinical Guidelines and Levels

Desirable LDL <100 mg/dL per AHA guidelines for low risk
Target LDL <70 mg/dL for very high CVD risk patients
HDL <40 mg/dL men or <50 mg/dL women considered low risk factor
Non-HDL goal <130 mg/dL for moderate risk per NCEP ATP III
Fasting lipid panel recommended every 4-6 years starting age 20
Total cholesterol 200-239 mg/dL borderline high
LDL 160-189 mg/dL high, warrants lifestyle intervention
Triglycerides <150 mg/dL normal, >500 mg/dL very high per AHA
Cascade screening for FH targets 1st degree relatives 80% yield
Apolipoprotein B target <90 mg/dL for high risk
Lp(a) >50 mg/dL considered risk enhancer per 2018 AHA
Risk assessment using PCE calculator 10-year ASCVD risk threshold 7.5%
Children of FH parents screened age 0-10, LDL >190 mg/dL diagnostic
Statin intensity high if LDL drop ≥50%, moderate 30-50%
ACC/AHA recommends lipid panel every 5 years age 40-75
ESC guideline LDL <55 mg/dL very high risk post-ACS
Optimal triglycerides <100 mg/dL for insulin resistance prevention
Direct LDL measurement preferred if triglycerides >400 mg/dL
HDL ≥60 mg/dL protective against CVD per NCEP
Universal screening lipids age 9-11 and 17-21 per AAP
Risk enhancers include high LDL-P >1000 nmol/L
Target apoB <80 mg/dL very high risk ESC 2019
Nonfasting lipids acceptable for initial screening per EAS
LDL ≥190 mg/dL in adults <40 initiates high intensity statin

Clinical Guidelines and Levels Interpretation

Think of your cholesterol numbers as a complicated but deeply revealing family drama, where the LDLs are the rowdy troublemakers you need to tightly manage, the HDLs are the noble but underappreciated peacekeepers, and your doctor is the director trying to stage an intervention before the triglycerides throw a truly disastrous party.

Epidemiology and Prevalence

According to the CDC, approximately 93 million U.S. adults aged 20 and older have elevated total cholesterol levels above 200 mg/dL
The World Health Organization reports that high cholesterol contributes to 2.6 million deaths annually worldwide, representing 4.4% of all global deaths
In Europe, the European Heart Network states that 54% of adults have total cholesterol levels above the recommended 5 mmol/L threshold
A NHANES survey from 2017-2018 found that 38.7% of U.S. adults had high LDL cholesterol (≥130 mg/dL)
Globally, 39% of adults aged 18+ had high cholesterol in 2018 per WHO STEPS survey data
In India, the ICMR-INDIAB study reported a prevalence of hypercholesterolemia at 13.9% in urban populations
Australian Bureau of Statistics data shows 32% of adults had high total cholesterol (>5.5 mmol/L) in 2011-12
In the UK, 59% of adults have cholesterol levels above 5 mmol/L according to BHF
Framingham Heart Study offspring cohort indicated 45% prevalence of high cholesterol in middle-aged adults
In China, the China Health and Nutrition Survey found 32.1% hypercholesterolemia prevalence in 2009
Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) reported 31.1% high LDL-C prevalence
In South Africa, 52.6% of adults had total cholesterol >5 mmol/L per WHO STEPS 2016
Japanese National Health and Nutrition Survey 2019 showed 27.4% dyslipidemia prevalence
In Mexico, ENSANUT 2018 found 47.5% high cholesterol in adults
Canadian Heart Health Surveys reported 42% prevalence of high cholesterol in 1986-1992
In Germany, DEGS1 survey 2008-2011 indicated 30.8% high total cholesterol
Italian Osservatorio Epidemiologico Cardiovascolare reported 38% hypercholesterolemia in adults
In Russia, 56.9% of adults had high cholesterol per 2013 survey
Swedish National Public Health Survey 2018 showed 25% high cholesterol prevalence
In the Netherlands, 60% of adults over 30 have elevated cholesterol per RIVM
New Zealand Health Survey 2017/18 found 32% high total cholesterol
In Turkey, TEKHARF study 2017 reported 46.2% hypercholesterolemia
Saudi Heart Association data indicates 41% prevalence in adults
In Egypt, 44.4% of adults have high cholesterol per NCD survey
Korean National Health Insurance data 2015 showed 19.6% severe hypercholesterolemia
In Iran, 40.2% prevalence from cross-sectional studies meta-analysis
Polish NATPOL 2011 study found 52% high cholesterol in adults
In Argentina, 34.4% hypercholesterolemia per 2018 survey
Norwegian HUNT3 study reported 45% elevated cholesterol
In Spain, ESCARVAL study 2008-2010 showed 39% high LDL-C

Epidemiology and Prevalence Interpretation

The world seems to be conducting a grim global science experiment where we've conclusively proven that consistently feeding our arteries a thick, waxy paint of cholesterol is a wildly effective way to kill millions of people annually.

Health Outcomes

High cholesterol increases CVD risk by 2.5-fold per 1 mmol/L LDL rise
Each 38.7 mg/dL LDL reduction lowers major vascular events by 22%
Low HDL (<40 mg/dL men) triples coronary heart disease risk
High cholesterol causes 4 million premature deaths yearly globally
Familial hypercholesterolemia untreated leads to 50% MI risk by age 50
Statin therapy reduces stroke risk by 21% per 1 mmol/L LDL drop
Non-HDL cholesterol >3.37 mmol/L doubles CVD mortality
Cholesterol embolization syndrome occurs in 1.4% post-angioplasty
High LDL accelerates aortic stenosis progression by 2-fold
Hypercholesterolemia increases PAD risk by 2.2-fold
In women, high cholesterol raises CVD death risk 4.5-fold post-menopause
Lp(a) >50 mg/dL elevates MI risk 2-3 fold
Cholesterol gallstones comprise 80% of gallstones in Western populations
High triglycerides (>5 mmol/L) increase pancreatitis risk 10-fold
Dyslipidemia contributes to 30% of ischemic strokes
In FH homozygotes, CVD events occur by age 20 in 75%
Remnant cholesterol >1 mmol/L raises CVD risk 40% per unit
High cholesterol links to 20% higher dementia risk
LDL >160 mg/dL triples carotid plaque progression
Statins reduce all-cause mortality by 14% in high cholesterol patients
High on-treatment LDL >70 mg/dL has 2-fold recurrent event risk
Cholesterol burden predicts 25% AFib risk increase
Xanthomas occur in 75% of FH heterozygotes untreated
Hypercholesterolemia worsens HF prognosis by 30%
LDL particle number >1300 nmol/L doubles CVD risk vs concentration
High cholesterol in youth predicts adult CVD 5-fold
Optimal total cholesterol <150 mg/dL reduces mortality 50%
HDL dysfunction increases MI risk 3-fold despite high levels

Health Outcomes Interpretation

It appears your cholesterol is throwing a rather aggressive retirement party for your cardiovascular system, with each guest bringing increasingly grim RSVPs.

Risk Factors and Correlates

Daily cholesterol intake averages 300-500 mg in Western diets
Obesity increases LDL cholesterol by 10-15% per 10 kg weight gain
Smoking raises LDL by 5-10% and lowers HDL by 10%
Type 2 diabetes elevates triglycerides and lowers HDL by 20-30%
Sedentary lifestyle correlates with 12% higher total cholesterol
Family history doubles risk of hypercholesterolemia
Postmenopausal women see 10-15% LDL rise due to estrogen decline
Trans fat intake raises LDL by 0.03 mmol/L per gram daily
Hypertension coexists with high cholesterol in 40% of cases
Age over 45 in men or 55 in women increases cholesterol risk by 2-fold
South Asian ethnicity has 20% higher dyslipidemia prevalence
Alcohol excess lowers HDL but raises triglycerides by 20%
Hypothyroidism elevates LDL by 30% via reduced clearance
Chronic kidney disease doubles hypercholesterolemia odds
Saturated fat >10% calories raises LDL by 10%
PCOS increases dyslipidemia risk by 70%
HIV infection on ART raises cholesterol by 10-20%
Stress hormones increase LDL by 10% acutely
Low fiber diet correlates with 15% higher cholesterol absorption
Metabolic syndrome present in 50% of high cholesterol patients
African American men have 10% lower average HDL than whites
Sleep apnea raises cholesterol by 10-15%
Corticosteroid use elevates cholesterol 20-30%
High glycemic index diets increase triglycerides 20%
Rheumatoid arthritis patients have 10% higher LDL
Beta-blockers raise triglycerides by 20-50%
Pregnancy increases total cholesterol by 25-50% in third trimester
Psoriasis doubles dyslipidemia risk
Shift work disrupts lipids with 8% higher cholesterol
High fructose intake raises LDL 10%
Nephrotic syndrome elevates cholesterol 3-5 fold

Risk Factors and Correlates Interpretation

Your cholesterol numbers are basically a gossip column about your entire life, revealing everything from your weekend hobbies to your great-grandmother’s secrets with unflinching, metabolic detail.

Treatment Efficacy

Statins reduce LDL by 20-60% dose-dependently
Ezetimibe adds 15-25% LDL reduction to statin
PCSK9 inhibitors lower LDL 50-70% in FH patients
Bempedoic acid reduces LDL 18% monotherapy
Plant sterols 2g/day lower LDL 10%
Niacin raises HDL 15-35% but no CVD benefit
Fibrates reduce triglycerides 20-50%
Aerobic exercise 150 min/week lowers LDL 5-10%
Mediterranean diet reduces LDL 10-15%
Soluble fiber 5-10g/day lowers LDL 5%
Weight loss 5-10% reduces total cholesterol 10%
Omega-3 4g/day lowers triglycerides 30%
Lomitapide in FH homozygotes reduces LDL 40-50%
Mipomersen ASO lowers LDL 40% in FH
Inclisiran siRNA reduces LDL 52% at 17 months
Portfolio diet lowers LDL 30% comparable to lovastatin
Rosuvastatin 20mg reduces LDL 55%
Lifestyle intervention alone lowers cholesterol 10-20% in mild cases
Bile acid sequestrants lower LDL 15-30%
Smoking cessation increases HDL 10% within 1 year
Soy protein 25g/day lowers LDL 3-5%
Nuts 1oz/day reduce LDL 5%
Green tea catechins lower LDL 5-10 mg/dL
Resistant starch intake reduces cholesterol absorption 10%
Probiotics lower LDL 5-10% in meta-analysis
Garlic supplements reduce total cholesterol 10-15 mg/dL short-term
Evolocumab reduces CVD events 20%
Alirocumab lowers LDL 62% max
Intensive statin doubles plaque regression vs moderate

Treatment Efficacy Interpretation

Our pharmaceutical artillery offers a direct assault on LDL cholesterol with potent effect, while lifestyle and dietary strategies provide a crucial supporting force that can meaningfully bolster the defenses and sometimes rival medication for milder cases.

Sources & References

Logos provided by Logo.dev